Cemdisiran Shows Therapeutic Potential in Phase 3 NIMBLE Trial for Generalized Myasthenia Gravis

Cemdisiran (Regeneron), an investigational small interfering RNA (siRNA) therapy targeting complement component 5 (C5), demonstrated statistically significant and clinically meaningful improvements in patients with acetylcholine receptor antibody–positive (AChR-Ab+) generalized myasthenia gravis (gMG) in the phase 3 NIMBLE trial, according to results published in The Lancet.¹ The findings, also presented at the American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois, suggest that durable complement suppression with infrequent subcutaneous dosing may offer an alternative approach to currently available C5 inhibitors.

Lead study author Tuan Vu, professor of neurology at the University of South Florida, told NeurologyLive at the conference that, “numerically, cemdisiran is very similar to the combination of therapies; the error bar overlaps so that you can't really say one is better than the other. The combination did not give you any additional advantage. Cemdisiran is given every three months, so the burden of treatment is really low and so far, and in the randomized controlled period, the safety data looked really good.”

Trial Overview and Efficacy Findings

The NIMBLE trial is a global, randomized, double-blind, placebo-controlled study evaluating cemdisiran in adults with generalized myasthenia gravis, with participants receiving subcutaneous cemdisiran every 12 weeks or placebo. The primary end point was change from baseline in Myasthenia Gravis–Activities of Daily Living (MG-ADL) score at week 24, with key secondary endpoints including Quantitative Myasthenia Gravis (QMG) score.¹

At week 24, patients treated with cemdisiran experienced a least squares mean reduction of 4.5 points in MG-ADL total score compared with 2.2 points in the placebo group, corresponding to a placebo-adjusted difference of –2.3 points (P <.001). In addition, a greater proportion of patients receiving cemdisiran achieved clinically meaningful improvement (≥3-point reduction) versus placebo (76.6% vs 44.1%). Improvements were observed as early as 2 weeks and were sustained through the study period, with no apparent waning of effect between doses.¹

Similarly, cemdisiran demonstrated superiority on QMG, with a mean reduction of 4.2 points compared with 1.5 points for placebo (difference, –2.8; P=.002). Nearly half of treated patients (48.4%) achieved a 5-point or greater improvement versus 19% in the placebo group.¹

Safety Profile

The overall safety profile of cemdisiran appeared comparable to placebo during the double-blind treatment period. Treatment-emergent adverse events (AEs) occurred in 69.2% of patients receiving cemdisiran and 77.1% of those receiving placebo. Common AEs included upper respiratory tract infection, headache, urinary tract infection, and nasopharyngitis, with most events being mild to moderate in severity.

Rates of infection were numerically lower in the cemdisiran group (27%) compared with placebo (40%), and no meningococcal infections or deaths were reported during the double-blind phase. One death due to pneumonia occurred during the extension period in a patient receiving cemdisiran with significant comorbidities and concomitant immunosuppressive therapy.¹

Vu added, “The treatment isn’t a monoclonal antibodies, which means patients can use it in combination with other drugs used in this space, including IVIg, plasma exchange, and and many of the monoclonals that are likely to come upstream in the future.”

Drug Background

Cemdisiran is an siRNA therapeutic designed to reduce hepatic production of complement C5, leading to sustained suppression of terminal complement activity.¹ This mechanism differs from monoclonal antibody–based C5 inhibitors, which directly bind circulating protein, and may enable longer dosing intervals. RNA interference–based therapies have been increasingly investigated across multiple disease areas, but cemdisiran would represent one of the first applications of this modality in neuromuscular autoimmune disease if approved.

Interpretation, Limitations, and Next Steps

The magnitude of improvement in MG-ADL and QMG observed in NIMBLE appears broadly consistent with prior studies of complement inhibition in gMG, though cross-trial comparisons should be interpreted cautiously due to differences in study design and populations.² The quarterly dosing schedule may represent a meaningful reduction in treatment burden; however, longer-term durability, safety, and real-world adherence remain to be established. Additionally, while the press release notes publication in The Lancet, full peer-reviewed data should be critically evaluated once independently reviewed.

Safety considerations remain particularly relevant for complement-targeting therapies, given the known risk of serious infections, including meningococcal disease, associated with this drug class.²

A regulatory submission for cemdisiran has been filed in the United States, with additional filings planned in other regions. Further data, including longer-term extension results and comparative analyses with existing therapies, will be important in defining its clinical role.

For more AAN coverage, click here.

REFERENCES
1. Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial. Regeneron Pharmaceuticals. News Release. April 21, 2026. Accessed: April 22, 2026. https://investor.regeneron.com/news-releases/news-release-details/cemdisiran-dosed-subcutaneously-every-12-weeks-demonstrates
2. Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti–acetylcholine receptor antibody–positive refractory generalized myasthenia gravis (REGAIN). Lancet Neurol. 2017;16(12):976-986. doi:10.1016/S1474-4422(17)30369-1